June 20, 2018
FDA letter updates risks of Type III endoleaks with aortic endovascular graft systems
Editor's Note
In a June 19 letter to healthcare providers, the Food & Drug Administration (FDA) says it continues to evaluate information from several sources, including manufacturers, on the risks associated with Type III endoleaks with various endovascular graft systems used for treatment of abdominal aortic aneurysms (AAAs) and aorto-iliac aneurysms.
Based on new information, the FDA says the Endologix AFX with Strata device is at greater risk for Type III endoleaks than other endovascular AAA graft systems.
Free Daily News
- Study: Music, preoperative education reduce cardiac surgery anxiety, improve recovery
- VA exempts over 300,000 healthcare jobs from federal hiring freeze
- Report: Hospital credit ratings showed mixed progress in 2024
- Proposed tariffs threaten medical device supply chain
- Providers push back on insurance cost-cutting hurdles
- EHR-integrated clinical decision support reduces unnecessary preoperative tests
- Infection control guidelines focus on regional anesthesia, pain management
- Study links high surgeon stress, positive patient outcomes
- Researchers recommend extending colonoscopy screening interval for low-risk patients
- New wrong-site surgery prevention toolkit seeing traction in ASCs
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement